Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2006

Open Access 01-12-2006 | Research

Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo

Authors: Peter Pyrko, Nathaniel Soriano, Adel Kardosh, Yen-Ting Liu, Jasim Uddin, Nicos A Petasis, Florence M Hofman, Ching-Shih Chen, Thomas C Chen, Axel H Schönthal

Published in: Molecular Cancer | Issue 1/2006

Login to get access

Abstract

Background

2,5-Dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex®) that lacks COX-2-inhibitory function. However, despite its inability to block COX-2 activity, DMC is able to potently mimic the anti-tumor effects of celecoxib in vitro and in vivo, indicating that both of these drugs are able to involve targets other than COX-2 to exert their recognized cytotoxic effects. However, the molecular components that are involved in mediating these drugs' apoptosis-stimulatory consequences are incompletely understood.

Results

We present evidence that celecoxib and DMC are able to down-regulate the expression of survivin, an anti-apoptotic protein that is highly expressed in tumor cells and known to confer resistance of such cells to anti-cancer treatments. Suppression of survivin is specific to these two drugs, as other coxibs (valdecoxib, rofecoxib) or traditional NSAIDs (flurbiprofen, indomethacin, sulindac) do not affect survivin expression at similar concentrations. The extent of survivin down-regulation by celecoxib and DMC in different tumor cell lines is somewhat variable, but closely correlates with the degree of drug-induced growth inhibition and apoptosis. When combined with irinotecan, a widely used anticancer drug, celecoxib and DMC greatly enhance the cytotoxic effects of this drug, in keeping with a model that suppression of survivin may be beneficial to sensitize cancer cells to chemotherapy. Remarkably, these effects are not restricted to in vitro conditions, but also take place in tumors from drug-treated animals, where both drugs similarly repress survivin, induce apoptosis, and inhibit tumor growth in vivo.

Conclusion

In consideration of survivin's recognized role as a custodian of tumor cell survival, our results suggest that celecoxib and DMC might exert their cytotoxic anti-tumor effects at least in part via the down-regulation of survivin – in a manner that does not require the inhibition of cyclooxygenase-2. Because inhibition of COX-2 appears to be negligible, it might be worthwhile to further evaluate DMC's potential as a non-coxib alternative to celecoxib for anti-cancer purposes.
Appendix
Available only for authorised users
Literature
1.
Howe LR, Dannenberg AJ: A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol. 2002, 29 (3 Suppl 11): 111-119. 10.1053/sonc.2002.34063CrossRefPubMed
2.
Parente L, Perretti M: Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol. 2003, 65 (2): 153-159. 10.1016/S0006-2952(02)01422-3CrossRefPubMed
3.
Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002, 94 (4): 252-266.CrossRefPubMed
4.
Dannenberg AJ, Subbaramaiah K: Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell. 2003, 4 (6): 431-436. 10.1016/S1535-6108(03)00310-6CrossRefPubMed
5.
FitzGerald GA: COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003, 2 (11): 879-890. 10.1038/nrd1225CrossRefPubMed
6.
Hawk ET, Viner JL, Dannenberg A, DuBois RN: COX-2 in cancer--a player that's defining the rules. J Natl Cancer Inst. 2002, 94 (8): 545-546.CrossRefPubMed
7.
Keller JJ, Giardiello FM: Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol Ther. 2003, 2 (4 Suppl 1): S140-9.PubMed
8.
Fitzgerald GA: Coxibs and cardiovascular disease. N Engl J Med. 2004, 351 (17): 1709-1711. 10.1056/NEJMp048288CrossRefPubMed
9.
Jenkins JK: Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. Food and Drug Administration (FDA) Decision Memo. 2005, On-line at: http://​wwwfdagov/​cder/​drug/​infopage/​COX2/​.​
10.
Juni P, Rutjes AW, Dieppe PA: Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?. BMJ. 2002, 324 (7349): 1287-1288. 10.1136/bmj.324.7349.1287PubMedCentralCrossRefPubMed
11.
Diperna CA, Bart RD, Sievers EM, Ma Y, Starnes VA, Bremner RM: Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma. J Thorac Cardiovasc Surg. 2003, 126 (4): 1129-1133. 10.1016/S0022-5223(03)00790-6CrossRefPubMed
12.
Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P, Mukhtar H: Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2004, 64 (9): 3334-3343. 10.1158/0008-5472.CAN-03-2422CrossRefPubMed
13.
Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000, 60 (5): 1306-1311.PubMed
14.
Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000, 60 (2): 293-297.PubMed
15.
Roh JL, Sung MW, Park SW, Heo DS, Lee DW, Kim KH: Celecoxib can prevent tumor growth and distant metastasis in postoperative setting. Cancer Res. 2004, 64 (9): 3230-3235. 10.1158/0008-5472.CAN-03-3050CrossRefPubMed
16.
Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, Davis TW, Masferrer JL: Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. 2002, 62 (20): 5778-5784.PubMed
17.
Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN: Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 2000, 60 (21): 6045-6051.PubMed
18.
Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E: Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem. 2002, 277 (31): 27613-27621. 10.1074/jbc.M201119200CrossRefPubMed
19.
Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, Rigas B: Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol. 1996, 52 (2): 237-245. 10.1016/0006-2952(96)00181-5CrossRefPubMed
20.
Kardosh A, Blumenthal M, Wang WJ, Chen TC, Schönthal AH: Differential Effects of Selective COX-2 Inhibitors on Cell Cycle Regulation and Proliferation of Glioblastoma Cell Lines. Cancer Biol Ther. 2004, 3: 9-16.CrossRef
21.
Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS: 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 2004, 64 (4): 1444-1451. 10.1158/0008-5472.CAN-03-2396CrossRefPubMed
22.
Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, Lippman SM: 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 2000, 60 (24): 6846-6850.PubMed
23.
Tegeder I, Pfeilschifter J, Geisslinger G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. Faseb J. 2001, 15 (12): 2057-2072. 10.1096/fj.01-0390revCrossRefPubMed
24.
Zhang X, Morham SG, Langenbach R, Young DA: Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med. 1999, 190 (4): 451-459. 10.1084/jem.190.4.451PubMedCentralCrossRefPubMed
25.
Kardosh A, Wang W, Uddin J, Petasis NA, Hofman F, Chen CC, Schönthal AH: Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther. 2005, 4 (5): 571-582.CrossRefPubMed
26.
Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS: Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst. 2002, 94 (8): 585-591.CrossRefPubMed
27.
Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS: From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004, 64 (12): 4309-4318. 10.1158/0008-5472.CAN-03-4063CrossRefPubMed
28.
Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS: Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst. 2002, 94 (23): 1745-1757.CrossRefPubMed
29.
Backhus LM, Petasis NA, Uddin J, Schönthal AH, Bart RD, Lin YG, Starnes VA, Bremner RM: Dimethyl-celecoxib as a novel non-COX-2 therapy in the treatment of lung cancer. J Thorac Cardiovasc Surg. 2005, 130: 1406-1412. 10.1016/j.jtcvs.2005.07.018CrossRefPubMed
30.
Johnson AJ, Song X, Hsu A, Chen C: Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv Enzyme Regul. 2001, 41: 221-235. 10.1016/S0065-2571(00)00015-7CrossRefPubMed
31.
Kardosh A, Soriano N, Liu YT, Uddin J, Petasis NA, Hofman F, Chen CC, Schönthal AH: Multi-target inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2-inhibitory analog of celecoxib. Blood. 2005, 106: 4330-4338. 10.1182/blood-2005-07-2819CrossRefPubMed
32.
Lin HP, Kulp SK, Tseng PH, Yang YT, Yang CC, Chen CS, Chen CS: Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol Cancer Ther. 2004, 3 (12): 1671-1680.PubMed
33.
Schönthal AH: Anti-tumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2. Neurosurgical Focus. 2006, 20 (4): E21 (p. 1-10).CrossRef
34.
Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997, 3 (8): 917-921. 10.1038/nm0897-917CrossRefPubMed
35.
Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003, 22 (53): 8581-8589. 10.1038/sj.onc.1207113CrossRefPubMed
36.
37.
Zaffaroni N, Pennati M, Daidone MG: Survivin as a target for new anticancer interventions. J Cell Mol Med. 2005, 9 (2): 360-372.CrossRefPubMed
38.
Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002, 277 (5): 3247-3257. 10.1074/jbc.M106643200CrossRefPubMed
39.
Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002, 21 (17): 2613-2622. 10.1038/sj.onc.1205353CrossRefPubMed
40.
Lohr K, Moritz C, Contente A, Dobbelstein M: p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem. 2003, 278 (35): 32507-32516. 10.1074/jbc.M212517200CrossRefPubMed
41.
Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999, 104 (3): 263-269.PubMedCentralCrossRefPubMed
42.
Waldman T, Kinzler KW, Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995, 55 (22): 5187-5190.PubMed
43.
Brandes AA: State-of-the-art treatment of high-grade brain tumors. Semin Oncol. 2003, 30 (6 Suppl 19): 4-9. 10.1053/j.seminoncol.2003.11.028CrossRefPubMed
44.
Furnari FB, Lin H, Huang HJS, Cavenee WK: Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA. 1997, 94: 12479-12484. 10.1073/pnas.94.23.12479PubMedCentralCrossRefPubMed
45.
Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK: Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Research. 1994, 54: 649-652.PubMed
46.
Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001, 276 (21): 18563-18569. 10.1074/jbc.M010787200CrossRefPubMed
47.
Evans JF, Kargman SL: Cancer and cyclooxygenase-2 (COX-2) inhibition. Curr Pharm Des. 2004, 10 (6): 627-634. 10.2174/1381612043453126CrossRefPubMed
48.
Phipps RP, Ryan E, Bernstein SH: Inhibition of cyclooxygenase-2: a new targeted therapy for B-cell lymphoma?. Leuk Res. 2004, 28 (2): 109-111. 10.1016/S0145-2126(03)00260-1CrossRefPubMed
49.
Chun KS, Surh YJ: Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol. 2004, 68 (6): 1089-1100. 10.1016/j.bcp.2004.05.031CrossRefPubMed
50.
Blumenthal RD, Waskewich C, Goldenberg DM, Lew W, Flefleh C, Burton J: Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. Clin Cancer Res. 2001, 7 (10): 3178-3185.PubMed
51.
Catalano A, Graciotti L, Rinaldi L, Raffaelli G, Rodilossi S, Betta P, Gianni W, Amoroso S, Procopio A: Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer. 2004, 109 (3): 322-328. 10.1002/ijc.11710CrossRefPubMed
52.
Kobayashi M, Nakamura S, Shibata K, Sahara N, Shigeno K, Shinjo K, Naito K, Ohnishi K: Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells. Eur J Haematol. 2005, 75 (3): 212-220. 10.1111/j.1600-0609.2005.00498.xCrossRefPubMed
53.
Lin J, Hsiao PW, Chiu TH, Chao JI: Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol. 2005, 70 (5): 658-667. 10.1016/j.bcp.2005.05.028CrossRefPubMed
54.
Zhang T, Fields JZ, Ehrlich SM, Boman BM: The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J Pharmacol Exp Ther. 2004, 308 (2): 434-437. 10.1124/jpet.103.059378CrossRefPubMed
55.
Krysan K, Dalwadi H, Sharma S, Pold M, Dubinett S: Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res. 2004, 64 (18): 6359-6362. 10.1158/0008-5472.CAN-04-1681CrossRefPubMed
56.
Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc'h N, Pold M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S, Dubinett S: COX-2-dependent stabilization of survivin in non-small cell lung cancer. Faseb J. 2004, 18 (1): 206-208.PubMed
57.
Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005, 5 (11): 876-885. 10.1038/nrc1736CrossRefPubMed
58.
Ding H, Han C, Zhu J, Chen CS, D'Ambrosio SM: Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer. 2005, 113 (5): 803-810. 10.1002/ijc.20639CrossRefPubMed
59.
Beltrami E, Plescia J, Wilkinson JC, Duckett CS, Altieri DC: Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J Biol Chem. 2004, 279 (3): 2077-2084. 10.1074/jbc.M309479200CrossRefPubMed
60.
Li F: Survivin study: what is the next wave?. J Cell Physiol. 2003, 197 (1): 8-29. 10.1002/jcp.10327CrossRefPubMed
61.
Coma S, Noe V, Lavarino C, Adan J, Rivas M, Lopez-Matas M, Pagan R, Mitjans F, Vilaro S, Piulats J, Ciudad CJ: Use of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis. Oligonucleotides. 2004, 14 (2): 100-113. 10.1089/1545457041526290CrossRefPubMed
62.
Cao C, Mu Y, Hallahan DE, Lu B: XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene. 2004, 23 (42): 7047-7052. 10.1038/sj.onc.1207929CrossRefPubMed
63.
Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q, Loeffler J: Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene. 2004, 23 (45): 7494-7506. 10.1038/sj.onc.1208049CrossRefPubMed
64.
Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, Price J, Chen J, Freeman M, Hallahan DE: Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res. 2004, 64 (8): 2840-2845. 10.1158/0008-5472.CAN-03-3547CrossRefPubMed
65.
Pennati M, Binda M, De Cesare M, Pratesi G, Folini M, Citti L, Daidone MG, Zunino F, Zaffaroni N: Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis. 2004, 25 (7): 1129-1136. 10.1093/carcin/bgh107CrossRefPubMed
66.
Wu J, Ling X, Pan D, Apontes P, Song L, Liang P, Altieri DC, Beerman T, Li F: Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem. 2005, 280 (10): 9745-9751. 10.1074/jbc.M409350200PubMedCentralCrossRefPubMed
67.
Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda M, Fukuoka M, Nakagawa K: Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer. 2005.
68.
Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE, Dowell JM, Friedman AH, Friedman HS: Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 2005, 103 (2): 329-338. 10.1002/cncr.20776CrossRefPubMed
69.
O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC, Altieri DC: Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A. 2000, 97 (24): 13103-13107. 10.1073/pnas.240390697PubMedCentralCrossRefPubMed
70.
O'Connor DS, Wall NR, Porter AC, Altieri DC: A p34(cdc2) survival checkpoint in cancer. Cancer Cell. 2002, 2 (1): 43-54. 10.1016/S1535-6108(02)00084-3CrossRefPubMed
71.
Chang CC, Heller JD, Kuo J, Huang RC: Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A. 2004, 101 (36): 13239-13244. 10.1073/pnas.0405407101PubMedCentralCrossRefPubMed
72.
Kim EH, Kim HS, Kim SU, Noh EJ, Lee JS, Choi KS: Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene. 2005, 24 (46): 6877-6889. 10.1038/sj.onc.1208851CrossRefPubMed
73.
Kim EH, Kim SU, Choi KS: Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene. 2005, 24 (5): 838-849. 10.1038/sj.onc.1208241CrossRefPubMed
74.
Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC: Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 2003, 63 (1): 230-235.PubMed
75.
Davies NM, McLachlan AJ, Day RO, Williams KM: Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000, 38 (3): 225-242. 10.2165/00003088-200038030-00003CrossRefPubMed
76.
McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999, 96 (1): 272-277. 10.1073/pnas.96.1.272PubMedCentralCrossRefPubMed
77.
Paulson SK, Kaprak TA, Gresk CJ, Fast DM, Baratta MT, Burton EG, Breau AP, Karim A: Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. Biopharm Drug Dispos. 1999, 20 (6): 293-299. 10.1002/(SICI)1099-081X(199909)20:6<293::AID-BDD188>3.0.CO;2-XCrossRefPubMed
78.
Raz A: Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem Pharmacol. 2002, 63 (3): 343-347. 10.1016/S0006-2952(01)00857-7CrossRefPubMed
79.
Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005, 352 (11): 1092-1102. 10.1056/NEJMoa050493CrossRefPubMed
80.
Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005, 352 (11). 10.1-1091.CrossRefPubMed
81.
RxList: Celecoxib. 2005 On-line at: http://​wwwrxlistcom/​cgi/​generic/​coxib_​wcphtm.​
82.
Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005, 352 (11). 10.1-1080.CrossRefPubMed
83.
Drazen JM: COX-2 inhibitors--a lesson in unexpected problems. N Engl J Med. 2005, 352 (11): 1131-1132. 10.1056/NEJMe058038CrossRefPubMed
84.
Editorial: Painful lessons. Nat Struct Mol Biol. 2005, 12 (3): 205-
85.
Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, , Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC: Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997, 40 (9): 1347-1365. 10.1021/jm960803qCrossRefPubMed
86.
Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K: 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem. 2000, 43 (5): 775-777. 10.1021/jm990577vCrossRefPubMed
87.
Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I: Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999, 290 (2): 551-560.PubMed
88.
Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R: The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett. 1999, 9 (13): 1773-1778. 10.1016/S0960-894X(99)00288-7CrossRefPubMed
89.
Harlow E, Lane D: Antibodies: A Laboratory Manual. 1988, Cold Spring Harbor, NY , Cold Spring Harbor Laboratory.
90.
Wu RC, Schönthal AH: Activation of p53-p21waf1 pathway in response to disruption of cell-matrix interactions. J Biol Chem. 1997, 272: 29091-29098. 10.1074/jbc.272.46.29091CrossRefPubMed
91.
Heatwole VM: TUNEL assay for apoptotic cells. Methods Mol Biol. 1999, 115: 141-148.PubMed
92.
Southern PJ, Berg P: Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. Journal of Molecular and Applied Genetics. 1982, 1: 327-341.PubMed
93.
Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K: Current Protocols in Molecular Biology. Edited by: Chanda VB. 1994, John Wiley & Sons, Inc..
94.
Katula KS, Wright KL, Paul H, Surman DR, Nuckolls FJ, Smith JW, Ting JP, Yates J, Cogswell JP: Cyclin-dependent kinase activation and S-phase induction of the cyclin B1 gene are linked through the CCAAT elements. Cell Growth Differ. 1997, 8 (7): 811-820.PubMed
95.
Li F, Altieri DC: Transcriptional analysis of human survivin gene expression. Biochem J. 1999, 344 Pt 2: 305-311. 10.1042/0264-6021:3440305PubMed
96.
Ohsugi Y, Gershwin ME, Owens RB, Nelson-Rees WA: Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X-irradiated nude mice. J Natl Cancer Inst. 1980, 65 (4): 715-718.PubMed
97.
Watanabe S, Shimosato Y, Kuroki M, Sato Y, Nakajima T: Transplantability of human lymphoid cell line, lymphoma, and leukemia in splenectomized and/or irradiated nude mice. Cancer Res. 1980, 40 (7): 2588-2595.PubMed
Metadata
Title
Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo
Authors
Peter Pyrko
Nathaniel Soriano
Adel Kardosh
Yen-Ting Liu
Jasim Uddin
Nicos A Petasis
Florence M Hofman
Ching-Shih Chen
Thomas C Chen
Axel H Schönthal
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2006
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-5-19

Other articles of this Issue 1/2006

Molecular Cancer 1/2006 Go to the issue

Research

Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas

Research

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

Short communication

The superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells

Research

P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity

Review

The cancer stem cell: Evidence for its origin as an injured autoreactive T Cell

Research

Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits